Connect with us


London-based start-up raises US$1.2m to help people with chronic disease



Ian Wharton and Brian Snyder, Aide Health founders

The London-based healthtech start-up Aide Health has secured $1.2m in pre-seed funding to support people with chronic disease.

Aide is a digital platform that helps patients and clinicians understand and manage long-term health conditions, currently affecting over 26 million people in the UK.

The company aims to help clinicians monitor health plans for people with chronic disease remotely, giving patients access to an app which acts as a co-pilot through their care.

In 50 per cent of cases, people with chronic disease struggle to follow the treatment as prescribed by their clinician, lowering their quality of life and placing added strain on health providers.

Aide’s service is currently being used by the NHS, with a pilot launched earlier this year supporting people aged between 18-75 with asthma or type-2 diabetes.

The company says it currently focuses on meeting the rising challenge of comorbidity and will soon be launching pathways for hypertension and chronic pain.

“Like many people, I know first-hand the frustrations of trying to manage long-term conditions,” said Ian Wharton, co-founder and CEO at Aide Health.

“Our goal is to give both patients and clinicians the tools and insights they need to have better conversations and make more informed treatment decisions together.

“The pilot in NHS England is our first step towards making Aide available to everyone with chronic illness.”

Nicholas Sharp, head of Hambro Perks Growth EIS Fund which led the funding round, said: “Ian and Brian’s vision and experience impressed us from the start, and we believe that Aide Health has the potential to be a hugely important tool for both clinicians and patients for managing long-term health conditions.

“Hambro Perks has a long track record of backing healthtech companies as part of our aim to invest in companies that make the world a better place.

“Aide Health and Ian’s team were therefore an obvious choice for us, and we look forward to supporting them on their growth journey.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories